BIOMAT Database Logo BIOMAT Database Logo

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. 1987

A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa

In an attempt to reduce some of the delayed sequelae associated with combined modality therapy in Hodgkin's disease, we randomly tested stages IIB, IIIA, and IIIB MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) v ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine). In 232 previously untreated patients, three cycles of either combination preceded and followed extensive irradiation. The complete remission rate was 80.7% following MOPP and 92.4% following ABVD (P less than .02). The 7-year results indicated that ABVD was superior to MOPP in terms of freedom from progression (80.8% v 62.8%; P less than .002), relapse-free survival (87.7% v 77.2%; P = .06), and overall survival (77.4% v 67.9%; P = .03). Moreover, the comparative iatrogenic morbidity showed that irreversible gonadal dysfunction as well as acute leukemia occurred only in patients subjected to MOPP, while cardiopulmonary studies failed to document significant laboratory differences between the two treatment groups. Present findings indicate that ABVD followed by extensive irradiation represents a valid therapeutic alternative to the widely used alkylating agent-containing regimens plus radiotherapy.

UI MeSH Term Description Entries
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008297 Male Males
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease.
August 1977, Cancer treatment reports,
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
January 1993, Haematologica,
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
July 1989, Journal of chemotherapy (Florence, Italy),
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
July 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
November 1992, The New England journal of medicine,
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
MOPP/ABVD chemotherapy for advanced Hodgkin's disease.
June 1986, Annals of internal medicine,
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
February 1995, Annals of oncology : official journal of the European Society for Medical Oncology,
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD.
January 1983, Acta Europaea fertilitatis,
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
Haematological toxicity compromises MOPP/ABVD chemotherapy in Hodgkin's disease.
May 1991, Clinical oncology (Royal College of Radiologists (Great Britain)),
A Santoro, and G Bonadonna, and P Valagussa, and R Zucali, and S Viviani, and F Villani, and A M Pagnoni, and V Bonfante, and R Musumeci, and F Crippa
Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
January 1989, Haematologica,
Copied contents to your clipboard!